|
Variable
|
T1
|
T2
|
T3
|
Time*group
|
Time*group*gender
|
|---|
|
Cholesterol (mg/dL)
|
|
PLA
|
155 ± 37
|
154 ± 34
|
161 ± 32
|
Time p = 0.07
|
G*T*Ge p = 0.38
|
|
LD
|
151 ± 28
|
150 ± 26
|
160 ± 28
|
G*T
p
= 0.001
|
|
HD
|
174 ± 33
|
162 ± 33
†
|
160 ± 32
†
|
|
HDL (mg/dL)
|
|
PLA
|
49 ± 10
|
51 ± 12
|
55 ± 12
|
Time p = 0.08
|
G*T*Ge p = 0.99
|
|
LD
|
47 ± 11
|
50 ± 12
|
51 ± 12
|
G*T p = 0.16
|
|
HD
|
53 ± 16
|
49 ± 15
|
52 ± 16
|
|
LDL (mg/dL)
|
|
PLA
|
89.4 ± 28.9
|
83.4 ± 28.9
|
87.7 ± 23.9
|
Time
p
= 0.001
|
G*T*Ge p = 0.38
|
|
LD
|
85.0 ± 19.8
|
78.9 ± 17.8
|
86.9 ± 22.2
|
G*T
p
= 0.024
|
|
HD
|
103.0 ± 22.1
|
89.3 ± 20.5
†
|
89.2 ± 19.9
†
|
|
Cholesterol/HDL
|
|
PLA
|
3.3 ± 0.9
|
3.1 ± 0.9
|
3.0 ± 0.8
|
Time p = 0.19
|
G*T*Ge p = 0.48
|
|
LD
|
3.2 ± 0.8
|
3.0 ± 0.8
|
3.2 ± 0.9
|
G*T p = 0.77
|
|
HD
|
35 ± 0.9
|
3.3 ± 0.9
|
3.3 ± 0.9
|
|
Triglycerides (mg/dL)
|
|
PLA
|
67 ± 25
|
77 ± 31
|
73 ± 31
|
Time p = 0.21
|
G*T*Ge p = 0.73
|
|
LD
|
80 ± 45
|
93 ± 50
|
97 ± 50
|
G*T p = 0.63
|
|
HD
|
87 ± 39
|
92 ± 40
|
83 ± 36
|
|
Glucose (mg/dL)
|
|
PLA
|
86 ± 8
|
86 ± 8
|
86 ± 6
|
Time p = 0.14
|
G*T*Ge p = 0.44
|
|
LD
|
87 ± 7
|
86 ± 8
|
90 ± 8
|
G*T p = 0.55
|
|
HD
|
84 ± 9
|
86 ± 9
|
86 ± 7
|
- Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
- Symbols: †, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
